CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-21 | NEIL GARRY ARTHUR Chief Executive Officer | Grant or award | +100,200 | 190,314 | ||
| 2026-05-15 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +3,000 | $12.65 | $38K | 6,622 |
| 2026-05-15 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −3,000 | $18.76 | $56K | 3,622 |
| 2026-05-15 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 128,625 | ||
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +18,606 | $9.88 | $184K | 19,029 |
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −18,606 | $24.12 | $449K | 423 |
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,606 | 168,094 | ||
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +77,905 | $12.65 | $985K | 81,527 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +28,650 | $8.04 | $230K | 110,177 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −27,538 | $18.03 | $496K | 82,639 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −5,000 | $19.65 | $98K | 77,639 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −44,944 | $21.20 | $953K | 32,695 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −19,015 | $22.41 | $426K | 13,680 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −10,058 | $22.88 | $230K | 3,622 |
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −77,905 | 131,625 | ||
| 2026-05-06 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −28,650 | 119,000 | ||
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +47,000 | $8.04 | $378K | 47,423 |
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −13,834 | $18.55 | $257K | 33,589 |
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −12,347 | $19.28 | $238K | 21,242 |
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −2,700 | $20.76 | $56K | 18,542 |
Page 4 of 11 · 202 trades